Stockscreener 앱 받기
1.88
4.57%
-0.09
전일 마감가:
$1.97
열려 있는:
$1.8
하루 거래량:
83,367
Relative Volume:
2.39
시가총액:
$44.31M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
-6.00%
1개월 성능:
-4.08%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$1.69
$1.93
1주일 범위
$1.69
$2.02
52주 변동 폭
$1.35
$3.50
Rein Therapeutics Inc Stock (RNTX) Company Profile
명칭
Rein Therapeutics Inc
전화
(737) 802-1989
주소
12407 N. MOPAC EXPY., AUSTIN
RNTX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RNTX
Rein Therapeutics Inc
|
1.88 | 44.31M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.45 | 115.69B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
529.24 | 53.25B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
307.99 | 39.22B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
577.89 | 35.78B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
269.63 | 27.68B | 3.81B | -644.79M | -669.77M | -6.24 |
Rein Therapeutics Inc Stock (RNTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-01-28 | 개시 | Rodman & Renshaw | Buy |
| 2017-07-24 | 개시 | BofA/Merrill | Buy |
| 2017-07-24 | 개시 | Jefferies | Buy |
| 2017-07-24 | 개시 | William Blair | Outperform |
Rein Therapeutics Inc 주식(RNTX)의 최신 뉴스
Rein Therapeutics study on clinical hold; Beam updates sickle cell therapy data - Endpoints News
Why RH Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket - Benzinga
US FDA puts on hold Rein Therapeutics' lung disease drug trial - Reuters
Rein Therapeutics Paused Its Phase 2 Renew Trial Of Lti-03 In The U.S. - marketscreener.com
Rein Therapeutics Pauses U.S. Enrollment for RENEW Trial - TipRanks
Rein Therapeutics pauses dosing in lung disease trial after US FDA places hold - TradingView
New National Poll Finds Overwhelming Majorities of Voters Want "America First" Reforms of Big Pharma’s Business Practices, Want to Limit Direct-to-Consumer Pharmaceutical Advertising, & Support President Trump’s Executive Order on Drug Pricing - Yahoo Finance
In Spain, short-term rentals surge despite bid to rein in overtourism - Yahoo
President Trump Should Rein in Biden Era Actions Targeting U.S. Businesses - Yahoo
Rein Therapeutics doses first subject in Phase II trial to treat IPF - Yahoo Finance
Pre-market Movers: SPRO, ASBP, IFRX, IMNN... - RTTNews
Rein Therapeutics Announces First Patient Dosed In Renew Phase 2 Trial Of Lti-03 In Patients With Ipf - marketscreener.com
IQVIA Holdings Inc. Announces First Patient Dosed in Renew Phase 2 Trial of Lti-03 in Patients with Ipf - marketscreener.com
IQV Collaborates with Rein Therapeutics on New IPF Trial | IQV S - GuruFocus
IQV Collaborates with Rein Therapeutics on New IPF Trial | IQV Stock News - GuruFocus
Breakthrough IPF Drug Enters Phase 2 Trial: Rein's Novel Treatment Could Transform Pulmonary Fibrosis Care - Stock Titan
Knee Pain Relief Through The Ear? New Study Says It's Possible - WFMZ.com
U.S. Had 1.5 Million Excess Deaths Following Pandemic - WFMZ.com
Exercise Improves Odds Against Cancer - WFMZ.com
Rein Therapeutics Announces First Patient Dosed in RENEW Phase 2 Trial of LTI-03 in Patients with IPF - PR Newswire
Recruitment underway for Phase 2 trial of IPF inhalation therapy - Pulmonary Fibrosis News
Prices for new US drugs doubled in 4 years as focus on rare disease grows - Reuters
Rein Therapeutics Presents Two Posters at the American Thoracic Society 2025 International Conference - Nasdaq
Rein Therapeutics Reports Q1 2025 Financial Results - TipRanks
Rein Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Rein Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update - GuruFocus
Rein Therapeutics Reports First Quarter 2025 Financial Results And Provides Business Update - marketscreener.com
Rein Therapeutics begins trial for idiopathic pulmonary fibrosis treatment - Yahoo Finance
Rein Therapeutics Announces Initiation Of Renew Phase 2 Trial Of Lti-03 In Patients With Ipf - marketscreener.com
Rein Therapeutics (RNTX) Begins Phase 2 Trial for IPF Treatment | RNTX Stock News - GuruFocus
Rein Therapeutics Announces Initiation of RENEW Phase 2 Trial of LTI-03 in Patients with IPF - PR Newswire
Rein Therapeutics Inc expected to post a loss of 24 cents a shareEarnings Preview - TradingView
Rein Therapeutics to integrate Qureight’s platform in trial of IPF treatment - Yahoo Finance
Rein Therapeutics and Qureight Ltd Announce Planned Integration of Deep-Learning Platform for Phase 2 Trial of LTI-03 in Patients with IPF - marketscreener.com
Rein Therapeutics to Present at The Citizens Life Sciences Conference 2025 - Citizen Tribune
Walmart reinstates minimum basket fee for SNAP orders - Yahoo
Rein Therapeutics Announces Abstract Accepted for Presentation at the American Thoracic Society 2025 International Conference - The Victoria Advocate
Breakthrough Lung Regeneration Study: Rein Therapeutics to Present New IPF Treatment Data at ATS 2025 - Stock Titan
Rein Therapeutics Granted Two Patents Covering the Novel Formulation and Administration Methods of Dry Powder LTI-03 for the Treatment of Respiratory Diseases - The Malaysian Reserve
Rein Therapeutics (RNTX) Secures Two Key Patents for Innovative Lung Treatment | RNTX Stock News - GuruFocus
Rein Therapeutics Granted Two Patents Covering The Novel Formulation And Administration Methods Of Dry Powder LTI-03 For Treatment Of Respiratory Diseases - marketscreener.com
Antibiotics Might Increase Risk of Childhood Asthma, Allergies - WFMZ.com
Muscle Quality Could Be Key To Successful Hip Replacement - WFMZ.com
Early Menopause Might Mean Greater Age-Related Brain Decline - WFMZ.com
Microplastics Could Be Contributing To Clogged Arteries - WFMZ.com
Psilocybin Use Dramatically Increasing In U.S. - WFMZ.com
Tesla Board Gets an Earful From State Treasurers Over Musk’s Focus - Yahoo Finance
A multicenter study to assess efficacy, safety, and tolerability of ropeginterferon alfa-2b-njft in patients with essential thrombocythemia in the US and Canada: EXCEED-ET trial - Frontiers
Rein Therapeutics Announces a Publication in Biomedicines on the - GuruFocus
Rein Therapeutics Announces a Publication in Biomedicines on the Immunomodulatory and Anti-fibrotic Properties of a Caveolin-1-Related Peptide in IPF and PASC-F - MarketScreener
Cancer-fighting implant shows promise in treating tumors - WFMZ.com
Rein Therapeutics Inc (RNTX) 재무 분석
Rein Therapeutics Inc (RNTX)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
Rein Therapeutics Inc 주식 (RNTX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| UNIVERSITY OF TEXAS/TEXAS AM I | 10% Owner |
Jun 17 '24 |
Sale |
3.25 |
4,707 |
15,298 |
1,746,549 |
1.91%
1.17%
자본화:
|
볼륨(24시간):